Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis

BACKGROUND: Myelofibrosis (MF) is a life-shortening complication of myeloproliferative neoplasms associated with ineffective hematopoiesis, splenomegaly, and progressive bone marrow (BM) fibrosis. The oral Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib has been shown to improve splenomegaly, sympto...

Descripción completa

Detalles Bibliográficos
Autores principales: Kvasnicka, Hans Michael, Thiele, Jürgen, Bueso-Ramos, Carlos E., Sun, William, Cortes, Jorge, Kantarjian, Hagop M., Verstovsek, Srdan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856218/
https://www.ncbi.nlm.nih.gov/pubmed/29544547
http://dx.doi.org/10.1186/s13045-018-0585-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856218/
https://www.ncbi.nlm.nih.gov/pubmed/29544547
http://dx.doi.org/10.1186/s13045-018-0585-5

Ejemplares similares